Sean Keane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sean Keane has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ignacio Martin-Loeches
Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St James’ Hospital, Dublin, Ireland
4 shared publications D.J. Buggy
Mater Misericordiae University Hospital, School of Medicine, University College Dublin, Ireland; Outcomes Research, Cleveland Clinic, Cleveland, OH, USA; EU COST Action 15204 Euro-Periscope
2 shared publicationsG. Flood
Mater Misericordiae University Hospital, School of Medicine, University College Dublin, Ireland
2 shared publicationsPierce Geoghegan
A Department of Anaesthesia and Critical Care Medicine , St. James's Hospital , Dublin , Ireland
2 shared publicationsV. Wall
Mater Misericordiae University Hospital, School of Medicine, University College Dublin, Ireland
2 shared publicationsAlejandro Rodriguez
F Critical Care Department , Hospital Universitario de Tarragona Joan XXIII, URV, IISPV, CIBERES , Tarragona , Spain
1 shared publication
Latest Publications
- 21 September 2026
- Published by Wiley in The Clinical Teacher
- Vol. 23 (5) , e70533
Beyond Retention in Undergraduate POCUS Education
- 21 September 2026
- Published by Wiley in The Clinical Teacher
- Vol. 23 (5) , e70533
Beyond Retention in Undergraduate POCUS Education
- Open Access
- 10 February 2026
- Published by Elsevier in SSRN Electronic Journal
Barriers and Enablers to Penicillin Allergy Assessment and Testing in the Intensive Care Unit: A Mixed-Methods Study
BackgroundPenicillin allergy labels (PALs) are frequently encountered, typically spurious, but not routinely assessed or tested in the ICU. With greater demand for effective antimicrobial stewardship, and growing support for non-allergist performed PAL assessment, enthusiasm for routine ICU-led PAL evaluation is increasing. However, we do not presently understand key factors needed to plan and deliver such a complex change in the clinical setting.MethodsWe conducted a convergent mixed-methods study combining an electronic survey of ICU healthcare staff with follow-up interviews. Participants included those working in ICUs with and without penicillin allergy assessment programmes. Survey data were analysed descriptively. Interview and free-text data underwent thematic analysis guided by the Theoretical Domains Framework (TDF). Quantitative and qualitative findings were integrated at the analysis stage.ResultsOverall, 113 healthcare staff completed the survey and 13 participated in interviews. Barriers to implementation included limited training, poor guideline awareness, low confidence in risk stratification and drug challenge procedures, perceived medico-legal risk, unclear ownership, and workload pressures. Enablers included clear governance structures, robust protocols, decision support tools, access to specialist advice, local champions, and audit and feedback mechanisms. Participants working in ICUs with established programmes described greater confidence, normalisation of practice, and reframing of risk through experience.ConclusionsVariation in ICU-led PAL assessment is driven primarily by organisational and behavioural factors rather than intrinsic clinical risk. Implementation itself appears to modify perceptions of safety and responsibility. Structured governance, experiential training, leadership, and reinforcement are central to sustainable adoption of penicillin allergy assessment in the ICU.
- 10 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBarriers and Enablers to Penicillin Allergy Assessment and Testing in the Intensive Care Unit: A Mixed-Methods Study
BackgroundPenicillin allergy labels (PALs) are frequently encountered, typically spurious, but not routinely assessed or tested in the ICU. With greater demand for effective antimicrobial stewardship, and growing support for non-allergist performed PAL assessment, enthusiasm for routine ICU-led PAL evaluation is increasing. However, we do not presently understand key factors needed to plan and deliver such a complex change in the clinical setting.MethodsWe conducted a convergent mixed-methods study combining an electronic survey of ICU healthcare staff with follow-up interviews. Participants included those working in ICUs with and without penicillin allergy assessment programmes. Survey data were analysed descriptively. Interview and free-text data underwent thematic analysis guided by the Theoretical Domains Framework (TDF). Quantitative and qualitative findings were integrated at the analysis stage.ResultsOverall, 113 healthcare staff completed the survey and 13 participated in interviews. Barriers to implementation included limited training, poor guideline awareness, low confidence in risk stratification and drug challenge procedures, perceived medico-legal risk, unclear ownership, and workload pressures. Enablers included clear governance structures, robust protocols, decision support tools, access to specialist advice, local champions, and audit and feedback mechanisms. Participants working in ICUs with established programmes described greater confidence, normalisation of practice, and reframing of risk through experience.ConclusionsVariation in ICU-led PAL assessment is driven primarily by organisational and behavioural factors rather than intrinsic clinical risk. Implementation itself appears to modify perceptions of safety and responsibility. Structured governance, experiential training, leadership, and reinforcement are central to sustainable adoption of penicillin allergy assessment in the ICU.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Pulmonary and Critical Care Medicine
- Vol. 19
A Narrative Review of Invasive Candidiasis in the Intensive Care Unit
Candida species is the most common cause of invasive fungal infection in the critically ill population admitted to the intensive care unit (ICU). Numerous risk factors for developing invasive candidiasis (IC) have been identified, and some, like the breach of protective barriers, abound within the ICU. Given that IC carries a significant mortality, morbidity, and healthcare cost burden, early diagnosis and treatment have become an essential topic of discussion. Several expert panels and task forces have been established to provide clear guidance on the management of IC. Unfortunately, IC remains a diagnostic and therapeutic challenge attributable to the changing fungal ecology of Candida species and the emergence of multidrug-resistant strains. This narrative review will focus on the following: (1) the incidence, outcomes, and changing epidemiology of IC globally; (2) the risk factors for developing IC; (3) IC risk stratification tools and their appropriate use; (4) diagnosis of IC; and (5) therapeutic agents and regimens.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Pulmonary and Critical Care Medicine
- Vol. 19
Open AccessA Narrative Review of Invasive Candidiasis in the Intensive Care Unit
Candida species is the most common cause of invasive fungal infection in the critically ill population admitted to the intensive care unit (ICU). Numerous risk factors for developing invasive candidiasis (IC) have been identified, and some, like the breach of protective barriers, abound within the ICU. Given that IC carries a significant mortality, morbidity, and healthcare cost burden, early diagnosis and treatment have become an essential topic of discussion. Several expert panels and task forces have been established to provide clear guidance on the management of IC. Unfortunately, IC remains a diagnostic and therapeutic challenge attributable to the changing fungal ecology of Candida species and the emergence of multidrug-resistant strains. This narrative review will focus on the following: (1) the incidence, outcomes, and changing epidemiology of IC globally; (2) the risk factors for developing IC; (3) IC risk stratification tools and their appropriate use; (4) diagnosis of IC; and (5) therapeutic agents and regimens.
- 4 October 2018
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 16 (11) , 839-847
Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis
Introduction Invasive candidiasis is the most common fungal infection affecting critically ill adults. International guidelines provide differing recommendations for first-line antifungal therapy, with echinocandins considered first-line in the majority. Amphotericin B has broad activity and low MIC resistance patterns across most Candida species, and guidance away from its use should be supported by the available evidence. Areas Covered A systematic literature review was conducted from August to September 2017 to determine whether treatment with echinocandins or other available drugs, namely voriconazole, confers a therapeutic or survival benefit over amphotericin B in critically ill adults with invasive candidiasis. Inclusion criteria were: 1) studies describing critically ill adults with invasive candidiasis, 2) studies describing therapeutic benefit or survival as an outcome, and 3) studies comparing amphotericin B, deoxycholate or lipid preparations, with any newer antifungal agent. 8 studies were included in the final review, incorporating 2352 unique patients. No difference in treatment efficacy or mortality outcomes in critically ill patients with invasive candidiasis receiving an amphotericin B formulation compared with those receiving an echinocandin or voriconazole was shown. Expert Commentary We conclude that in the existing literature, there is no evidence that choice between echinocandins, voriconazole, or amphotericin B formulations as first line therapy for critically ill adults with invasive candidiasis is associated with a therapeutic or survival benefit. Clinicians must therefore consider other factors in selection of first line therapy
- 4 October 2018
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 16 (11) , 839-847
Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis
Introduction Invasive candidiasis is the most common fungal infection affecting critically ill adults. International guidelines provide differing recommendations for first-line antifungal therapy, with echinocandins considered first-line in the majority. Amphotericin B has broad activity and low MIC resistance patterns across most Candida species, and guidance away from its use should be supported by the available evidence. Areas Covered A systematic literature review was conducted from August to September 2017 to determine whether treatment with echinocandins or other available drugs, namely voriconazole, confers a therapeutic or survival benefit over amphotericin B in critically ill adults with invasive candidiasis. Inclusion criteria were: 1) studies describing critically ill adults with invasive candidiasis, 2) studies describing therapeutic benefit or survival as an outcome, and 3) studies comparing amphotericin B, deoxycholate or lipid preparations, with any newer antifungal agent. 8 studies were included in the final review, incorporating 2352 unique patients. No difference in treatment efficacy or mortality outcomes in critically ill patients with invasive candidiasis receiving an amphotericin B formulation compared with those receiving an echinocandin or voriconazole was shown. Expert Commentary We conclude that in the existing literature, there is no evidence that choice between echinocandins, voriconazole, or amphotericin B formulations as first line therapy for critically ill adults with invasive candidiasis is associated with a therapeutic or survival benefit. Clinicians must therefore consider other factors in selection of first line therapy
- 1 July 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (S18) , S2133-S2137
Change is in the air: dying to breathe oxygen in acute respiratory distress syndrome?
Change is in the air: dying to breathe oxygen in acute respiratory distress syndrome?
- 1 July 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (S18) , S2133-S2137
Change is in the air: dying to breathe oxygen in acute respiratory distress syndrome?
Change is in the air: dying to breathe oxygen in acute respiratory distress syndrome?
- 25 March 2018
- Published by Wiley in Pediatric Anesthesia
- Vol. 28 (4) , 372-373
Parent and anesthetist attitudes toward rectal analgesic suppositories in pediatric daycase surgery: A multi‐center cross‐sectional survey
- 25 March 2018
- Published by Wiley in Pediatric Anesthesia
- Vol. 28 (4) , 372-373
Parent and anesthetist attitudes toward rectal analgesic suppositories in pediatric daycase surgery: A multi‐center cross‐sectional survey
- 1 January 2018
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 120 (1) , e3-e4
Single-shot pectoral plane block vs continuous local anaesthetic infusion analgesia or both pectoral plane block and local anaesthetic infusion after breast surgery: a randomised, double blind, non-inferiority trial
- 1 January 2018
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 120 (1) , e3-e4
Single-shot pectoral plane block vs continuous local anaesthetic infusion analgesia or both pectoral plane block and local anaesthetic infusion after breast surgery: a randomised, double blind, non-inferiority trial
- Open Access
- 30 June 2017
- Published by ClinMed International Library in Journal of Otolaryngology and Rhinology
- Vol. 3 (1)
Inadvertent Vocal Fold Polypectomy During Tracheal Intubation; A Case Report
A 48-year-old male presented for microlaryngoscopy and vocal fold polypectomy, which was complicated by polyp displacement into the lower respiratory airway during direct laryngoscopy and tracheal intubation. It is the first reported incidence of such a case. Following preoperative assessment and preparation, anaesthesia was induced and the airway secured using direct laryngoscopy and tracheal intubation with a microlaryngoscopy tube (MLT), which was reported uneventful. On microlaryngoscopy, the surgeon who had diagnosed the polyp in the outpatient clinic noted the polyp had disappeared. It was determined that the polyp had been sheared by the MLT. A fibreoptic scope was passed via the MLT, showing the polyp at the entrance to the right main bronchus. The polyp was successfully extracted via rigid bronchoscopy. The subsequent surgery and post-operative recovery were otherwise uneventful. Complications of bronchial occlusion were avoided by early recognition of the issue. Case reflection identifies many potential learning points.
- 30 June 2017
- Published by ClinMed International Library in Journal of Otolaryngology and Rhinology
- Vol. 3 (1)
Open AccessInadvertent Vocal Fold Polypectomy During Tracheal Intubation; A Case Report
A 48-year-old male presented for microlaryngoscopy and vocal fold polypectomy, which was complicated by polyp displacement into the lower respiratory airway during direct laryngoscopy and tracheal intubation. It is the first reported incidence of such a case. Following preoperative assessment and preparation, anaesthesia was induced and the airway secured using direct laryngoscopy and tracheal intubation with a microlaryngoscopy tube (MLT), which was reported uneventful. On microlaryngoscopy, the surgeon who had diagnosed the polyp in the outpatient clinic noted the polyp had disappeared. It was determined that the polyp had been sheared by the MLT. A fibreoptic scope was passed via the MLT, showing the polyp at the entrance to the right main bronchus. The polyp was successfully extracted via rigid bronchoscopy. The subsequent surgery and post-operative recovery were otherwise uneventful. Complications of bronchial occlusion were avoided by early recognition of the issue. Case reflection identifies many potential learning points.